NCT02653313View on ClinicalTrials.gov

Parvovirus H-1 (ParvOryx) in Patients With Metastatic Inoperable Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions
Carcinoma, Pancreatic Ductal
Interventions
DRUG

Parvovirus H-1 (H-1PV)

"Parvovirus H-1 administered at three increasing dose levels , according to the following schedule: i) 4 daily intravenous infusions of 10% of the total dose over 2 hours on 4 consecutive days, ii) direct injection of 60% of the total dose into a hepatic metastasis of the pancreatic cancer.~The total dose levels are: 1E09, 5E09 and 1E10 pfu."

Trial Locations (1)

69120

National Center for Tumor Diseases (NCT), Heidelberg

All Listed Sponsors
lead

Oryx GmbH & Co. KG

INDUSTRY

NCT02653313 - Parvovirus H-1 (ParvOryx) in Patients With Metastatic Inoperable Pancreatic Cancer | Biotech Hunter | Biotech Hunter